DNA Sequencing In Drugs Discovery Comprehensive Study by Type (Shotgun (Sanger) DNA Sequencing, High Throughput), Method (Maxam And Gilbert Method, Chain Termination Method, Semiautomated Method, Automated Method), End User (Hospital, Clinical Laboratories, Forensics) Players and Region - Global Market Outlook to 2027

DNA Sequencing In Drugs Discovery Market by XX Submarkets | Forecast Years 2022-2027  

  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
About DNA Sequencing In Drugs Discovery
DNA Sequencing In Drug Discovery used for diagnosis and treatment of diseases. DNA sequencing allows healthcare practitioners to determine if the gene or the region that regulates a genes contains changes. Sequencing has the power to revolutionize food safety and sustainable agriculture including animal, plant and public health, improving agriculture through effective plant and animal breeding and reducing the risks from disease outbreaks. Additionally, DNA sequencing in drug discovery can be used for protecting and improving the natural environment for both humans and wildlife.

AttributesDetails
Study Period2017-2027
Base Year2021
UnitValue (USD Million)


The market for DNA Sequencing In Drug Discovery is highly competitive with several global as well as local players in the market. The global players are trying various strategies such as product innovation and using various marketing strategies to gain a higher market share. Analyst at AMA Research estimates that United States Players will contribute the maximum growth to Global DNA Sequencing In Drugs Discovery market throughout the forecasted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

Illumina (United States), Bio Basic (Canada), Pacific Biosciences (United States), QIAGEN (Germany), F. Hoffmann-La Roche Ltd. (Switzerland), Thermo Fischer Scientific Inc. (United States) and Promega Corporation (United States) are some of the key players that are part of study coverage.

Segmentation Overview
AMA Research has segmented the market of Global DNA Sequencing In Drugs Discovery market by Type (Shotgun (Sanger) DNA Sequencing and High Throughput) and Region.



On the basis of geography, the market of DNA Sequencing In Drugs Discovery has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by Method, the sub-segment i.e. Maxam And Gilbert Method will boost the DNA Sequencing In Drugs Discovery market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by End User, the sub-segment i.e. Hospital will boost the DNA Sequencing In Drugs Discovery market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

DNA Sequencing In Drugs Discovery Market Dynamics:
AttributesDetails
Growth Drivers
  • Rising Demand in the Making of Novel Drugs
  • Rising Demand in Various Polymerase Chain Reactions
Influencing Trends
  • Technological Innovation and Advancement in DNA Sequencing in Drug Discovery
Restraints
  • Less Efficient At Predicting Some Conditions Than Biochemical Tests
Road Blocks / Challenges
  • Lack of Knowledge about DNA Sequencing
  • Lack of Expertise and Professionals for DNA Sequencing Technology
Gaps & Opportunities
  • Growth in Healthcare Innovation and Next Generation DNA Sequencing Technology


Market Leaders and their expansionary development strategies
On 9 June 2022, Illumina, Inc., A Global Leader In DNA Sequencing And Array-Based Technologies, And Deerfield Management, A Healthcare Investment Management Firm, Announced A Five-Year Partnership To Apply A Genetic-Led Approach To The Discovery And Development Of Novel Therapies For Diseases With Unmet Medical Needs. The Partnership Aims To Leverage Genomic Tools And Genetic Knowledge To Select Programs With A Higher Probability Of Success In Order To Lower Research And Development Costs And Accelerate The Approval Of Cutting-Edge Therapies.



Key Target Audience
DNA Sequencing In Drug Discovery, New Entrants and Investors, Venture Capitalists, Government Bodies, Corporate Entities, Government and Private Research Organizations and Others

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have a better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with the purpose to understand the companies positioning regarding the market value, volume, and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply a number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders, etc., and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, the analyst team keeps preparing a set of questionnaires, and after getting the appointee list; the target audience is then tapped and segregated with various mediums and channels that are feasible for making connections that including email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey, etc.

Report Objectives / Segmentation Covered

By Type
  • Shotgun (Sanger) DNA Sequencing
  • High Throughput
By Method
  • Maxam And Gilbert Method
  • Chain Termination Method
  • Semiautomated Method
  • Automated Method

By End User
  • Hospital
  • Clinical Laboratories
  • Forensics

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Rising Demand in the Making of Novel Drugs
      • 3.2.2. Rising Demand in Various Polymerase Chain Reactions
    • 3.3. Market Challenges
      • 3.3.1. Lack of Knowledge about DNA Sequencing
      • 3.3.2. Lack of Expertise and Professionals for DNA Sequencing Technology
    • 3.4. Market Trends
      • 3.4.1. Technological Innovation and Advancement in DNA Sequencing in Drug Discovery
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global DNA Sequencing In Drugs Discovery, by Type, Method, End User and Region (value and price ) (2016-2021)
    • 5.1. Introduction
    • 5.2. Global DNA Sequencing In Drugs Discovery (Value)
      • 5.2.1. Global DNA Sequencing In Drugs Discovery by: Type (Value)
        • 5.2.1.1. Shotgun (Sanger) DNA Sequencing
        • 5.2.1.2. High Throughput
      • 5.2.2. Global DNA Sequencing In Drugs Discovery by: Method (Value)
        • 5.2.2.1. Maxam And Gilbert Method
        • 5.2.2.2. Chain Termination Method
        • 5.2.2.3. Semiautomated Method
        • 5.2.2.4. Automated Method
      • 5.2.3. Global DNA Sequencing In Drugs Discovery by: End User (Value)
        • 5.2.3.1. Hospital
        • 5.2.3.2. Clinical Laboratories
        • 5.2.3.3. Forensics
      • 5.2.4. Global DNA Sequencing In Drugs Discovery Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Australia
          • 5.2.4.2.6. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
    • 5.3. Global DNA Sequencing In Drugs Discovery (Price)
      • 5.3.1. Global DNA Sequencing In Drugs Discovery by: Type (Price)
  • 6. DNA Sequencing In Drugs Discovery: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
    • 6.2. Peer Group Analysis (2021)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Illumina (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Bio Basic (Canada)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Pacific Biosciences (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. QIAGEN (Germany)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. F. Hoffmann-La Roche Ltd. (Switzerland)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Thermo Fischer Scientific Inc. (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Promega Corporation (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
  • 7. Global DNA Sequencing In Drugs Discovery Sale, by Type, Method, End User and Region (value and price ) (2022-2027)
    • 7.1. Introduction
    • 7.2. Global DNA Sequencing In Drugs Discovery (Value)
      • 7.2.1. Global DNA Sequencing In Drugs Discovery by: Type (Value)
        • 7.2.1.1. Shotgun (Sanger) DNA Sequencing
        • 7.2.1.2. High Throughput
      • 7.2.2. Global DNA Sequencing In Drugs Discovery by: Method (Value)
        • 7.2.2.1. Maxam And Gilbert Method
        • 7.2.2.2. Chain Termination Method
        • 7.2.2.3. Semiautomated Method
        • 7.2.2.4. Automated Method
      • 7.2.3. Global DNA Sequencing In Drugs Discovery by: End User (Value)
        • 7.2.3.1. Hospital
        • 7.2.3.2. Clinical Laboratories
        • 7.2.3.3. Forensics
      • 7.2.4. Global DNA Sequencing In Drugs Discovery Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Australia
          • 7.2.4.2.6. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
    • 7.3. Global DNA Sequencing In Drugs Discovery (Price)
      • 7.3.1. Global DNA Sequencing In Drugs Discovery by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. DNA Sequencing In Drugs Discovery: by Type(USD Million)
  • Table 2. DNA Sequencing In Drugs Discovery Shotgun (Sanger) DNA Sequencing , by Region USD Million (2016-2021)
  • Table 3. DNA Sequencing In Drugs Discovery High Throughput , by Region USD Million (2016-2021)
  • Table 4. DNA Sequencing In Drugs Discovery: by Method(USD Million)
  • Table 5. DNA Sequencing In Drugs Discovery Maxam And Gilbert Method , by Region USD Million (2016-2021)
  • Table 6. DNA Sequencing In Drugs Discovery Chain Termination Method , by Region USD Million (2016-2021)
  • Table 7. DNA Sequencing In Drugs Discovery Semiautomated Method , by Region USD Million (2016-2021)
  • Table 8. DNA Sequencing In Drugs Discovery Automated Method , by Region USD Million (2016-2021)
  • Table 9. DNA Sequencing In Drugs Discovery: by End User(USD Million)
  • Table 10. DNA Sequencing In Drugs Discovery Hospital , by Region USD Million (2016-2021)
  • Table 11. DNA Sequencing In Drugs Discovery Clinical Laboratories , by Region USD Million (2016-2021)
  • Table 12. DNA Sequencing In Drugs Discovery Forensics , by Region USD Million (2016-2021)
  • Table 13. South America DNA Sequencing In Drugs Discovery, by Country USD Million (2016-2021)
  • Table 14. South America DNA Sequencing In Drugs Discovery, by Type USD Million (2016-2021)
  • Table 15. South America DNA Sequencing In Drugs Discovery, by Method USD Million (2016-2021)
  • Table 16. South America DNA Sequencing In Drugs Discovery, by End User USD Million (2016-2021)
  • Table 17. Brazil DNA Sequencing In Drugs Discovery, by Type USD Million (2016-2021)
  • Table 18. Brazil DNA Sequencing In Drugs Discovery, by Method USD Million (2016-2021)
  • Table 19. Brazil DNA Sequencing In Drugs Discovery, by End User USD Million (2016-2021)
  • Table 20. Argentina DNA Sequencing In Drugs Discovery, by Type USD Million (2016-2021)
  • Table 21. Argentina DNA Sequencing In Drugs Discovery, by Method USD Million (2016-2021)
  • Table 22. Argentina DNA Sequencing In Drugs Discovery, by End User USD Million (2016-2021)
  • Table 23. Rest of South America DNA Sequencing In Drugs Discovery, by Type USD Million (2016-2021)
  • Table 24. Rest of South America DNA Sequencing In Drugs Discovery, by Method USD Million (2016-2021)
  • Table 25. Rest of South America DNA Sequencing In Drugs Discovery, by End User USD Million (2016-2021)
  • Table 26. Asia Pacific DNA Sequencing In Drugs Discovery, by Country USD Million (2016-2021)
  • Table 27. Asia Pacific DNA Sequencing In Drugs Discovery, by Type USD Million (2016-2021)
  • Table 28. Asia Pacific DNA Sequencing In Drugs Discovery, by Method USD Million (2016-2021)
  • Table 29. Asia Pacific DNA Sequencing In Drugs Discovery, by End User USD Million (2016-2021)
  • Table 30. China DNA Sequencing In Drugs Discovery, by Type USD Million (2016-2021)
  • Table 31. China DNA Sequencing In Drugs Discovery, by Method USD Million (2016-2021)
  • Table 32. China DNA Sequencing In Drugs Discovery, by End User USD Million (2016-2021)
  • Table 33. Japan DNA Sequencing In Drugs Discovery, by Type USD Million (2016-2021)
  • Table 34. Japan DNA Sequencing In Drugs Discovery, by Method USD Million (2016-2021)
  • Table 35. Japan DNA Sequencing In Drugs Discovery, by End User USD Million (2016-2021)
  • Table 36. India DNA Sequencing In Drugs Discovery, by Type USD Million (2016-2021)
  • Table 37. India DNA Sequencing In Drugs Discovery, by Method USD Million (2016-2021)
  • Table 38. India DNA Sequencing In Drugs Discovery, by End User USD Million (2016-2021)
  • Table 39. South Korea DNA Sequencing In Drugs Discovery, by Type USD Million (2016-2021)
  • Table 40. South Korea DNA Sequencing In Drugs Discovery, by Method USD Million (2016-2021)
  • Table 41. South Korea DNA Sequencing In Drugs Discovery, by End User USD Million (2016-2021)
  • Table 42. Australia DNA Sequencing In Drugs Discovery, by Type USD Million (2016-2021)
  • Table 43. Australia DNA Sequencing In Drugs Discovery, by Method USD Million (2016-2021)
  • Table 44. Australia DNA Sequencing In Drugs Discovery, by End User USD Million (2016-2021)
  • Table 45. Rest of Asia-Pacific DNA Sequencing In Drugs Discovery, by Type USD Million (2016-2021)
  • Table 46. Rest of Asia-Pacific DNA Sequencing In Drugs Discovery, by Method USD Million (2016-2021)
  • Table 47. Rest of Asia-Pacific DNA Sequencing In Drugs Discovery, by End User USD Million (2016-2021)
  • Table 48. Europe DNA Sequencing In Drugs Discovery, by Country USD Million (2016-2021)
  • Table 49. Europe DNA Sequencing In Drugs Discovery, by Type USD Million (2016-2021)
  • Table 50. Europe DNA Sequencing In Drugs Discovery, by Method USD Million (2016-2021)
  • Table 51. Europe DNA Sequencing In Drugs Discovery, by End User USD Million (2016-2021)
  • Table 52. Germany DNA Sequencing In Drugs Discovery, by Type USD Million (2016-2021)
  • Table 53. Germany DNA Sequencing In Drugs Discovery, by Method USD Million (2016-2021)
  • Table 54. Germany DNA Sequencing In Drugs Discovery, by End User USD Million (2016-2021)
  • Table 55. France DNA Sequencing In Drugs Discovery, by Type USD Million (2016-2021)
  • Table 56. France DNA Sequencing In Drugs Discovery, by Method USD Million (2016-2021)
  • Table 57. France DNA Sequencing In Drugs Discovery, by End User USD Million (2016-2021)
  • Table 58. Italy DNA Sequencing In Drugs Discovery, by Type USD Million (2016-2021)
  • Table 59. Italy DNA Sequencing In Drugs Discovery, by Method USD Million (2016-2021)
  • Table 60. Italy DNA Sequencing In Drugs Discovery, by End User USD Million (2016-2021)
  • Table 61. United Kingdom DNA Sequencing In Drugs Discovery, by Type USD Million (2016-2021)
  • Table 62. United Kingdom DNA Sequencing In Drugs Discovery, by Method USD Million (2016-2021)
  • Table 63. United Kingdom DNA Sequencing In Drugs Discovery, by End User USD Million (2016-2021)
  • Table 64. Netherlands DNA Sequencing In Drugs Discovery, by Type USD Million (2016-2021)
  • Table 65. Netherlands DNA Sequencing In Drugs Discovery, by Method USD Million (2016-2021)
  • Table 66. Netherlands DNA Sequencing In Drugs Discovery, by End User USD Million (2016-2021)
  • Table 67. Rest of Europe DNA Sequencing In Drugs Discovery, by Type USD Million (2016-2021)
  • Table 68. Rest of Europe DNA Sequencing In Drugs Discovery, by Method USD Million (2016-2021)
  • Table 69. Rest of Europe DNA Sequencing In Drugs Discovery, by End User USD Million (2016-2021)
  • Table 70. MEA DNA Sequencing In Drugs Discovery, by Country USD Million (2016-2021)
  • Table 71. MEA DNA Sequencing In Drugs Discovery, by Type USD Million (2016-2021)
  • Table 72. MEA DNA Sequencing In Drugs Discovery, by Method USD Million (2016-2021)
  • Table 73. MEA DNA Sequencing In Drugs Discovery, by End User USD Million (2016-2021)
  • Table 74. Middle East DNA Sequencing In Drugs Discovery, by Type USD Million (2016-2021)
  • Table 75. Middle East DNA Sequencing In Drugs Discovery, by Method USD Million (2016-2021)
  • Table 76. Middle East DNA Sequencing In Drugs Discovery, by End User USD Million (2016-2021)
  • Table 77. Africa DNA Sequencing In Drugs Discovery, by Type USD Million (2016-2021)
  • Table 78. Africa DNA Sequencing In Drugs Discovery, by Method USD Million (2016-2021)
  • Table 79. Africa DNA Sequencing In Drugs Discovery, by End User USD Million (2016-2021)
  • Table 80. North America DNA Sequencing In Drugs Discovery, by Country USD Million (2016-2021)
  • Table 81. North America DNA Sequencing In Drugs Discovery, by Type USD Million (2016-2021)
  • Table 82. North America DNA Sequencing In Drugs Discovery, by Method USD Million (2016-2021)
  • Table 83. North America DNA Sequencing In Drugs Discovery, by End User USD Million (2016-2021)
  • Table 84. United States DNA Sequencing In Drugs Discovery, by Type USD Million (2016-2021)
  • Table 85. United States DNA Sequencing In Drugs Discovery, by Method USD Million (2016-2021)
  • Table 86. United States DNA Sequencing In Drugs Discovery, by End User USD Million (2016-2021)
  • Table 87. Canada DNA Sequencing In Drugs Discovery, by Type USD Million (2016-2021)
  • Table 88. Canada DNA Sequencing In Drugs Discovery, by Method USD Million (2016-2021)
  • Table 89. Canada DNA Sequencing In Drugs Discovery, by End User USD Million (2016-2021)
  • Table 90. Mexico DNA Sequencing In Drugs Discovery, by Type USD Million (2016-2021)
  • Table 91. Mexico DNA Sequencing In Drugs Discovery, by Method USD Million (2016-2021)
  • Table 92. Mexico DNA Sequencing In Drugs Discovery, by End User USD Million (2016-2021)
  • Table 93. DNA Sequencing In Drugs Discovery: by Type(USD/Units)
  • Table 94. Company Basic Information, Sales Area and Its Competitors
  • Table 95. Company Basic Information, Sales Area and Its Competitors
  • Table 96. Company Basic Information, Sales Area and Its Competitors
  • Table 97. Company Basic Information, Sales Area and Its Competitors
  • Table 98. Company Basic Information, Sales Area and Its Competitors
  • Table 99. Company Basic Information, Sales Area and Its Competitors
  • Table 100. Company Basic Information, Sales Area and Its Competitors
  • Table 101. DNA Sequencing In Drugs Discovery: by Type(USD Million)
  • Table 102. DNA Sequencing In Drugs Discovery Shotgun (Sanger) DNA Sequencing , by Region USD Million (2022-2027)
  • Table 103. DNA Sequencing In Drugs Discovery High Throughput , by Region USD Million (2022-2027)
  • Table 104. DNA Sequencing In Drugs Discovery: by Method(USD Million)
  • Table 105. DNA Sequencing In Drugs Discovery Maxam And Gilbert Method , by Region USD Million (2022-2027)
  • Table 106. DNA Sequencing In Drugs Discovery Chain Termination Method , by Region USD Million (2022-2027)
  • Table 107. DNA Sequencing In Drugs Discovery Semiautomated Method , by Region USD Million (2022-2027)
  • Table 108. DNA Sequencing In Drugs Discovery Automated Method , by Region USD Million (2022-2027)
  • Table 109. DNA Sequencing In Drugs Discovery: by End User(USD Million)
  • Table 110. DNA Sequencing In Drugs Discovery Hospital , by Region USD Million (2022-2027)
  • Table 111. DNA Sequencing In Drugs Discovery Clinical Laboratories , by Region USD Million (2022-2027)
  • Table 112. DNA Sequencing In Drugs Discovery Forensics , by Region USD Million (2022-2027)
  • Table 113. South America DNA Sequencing In Drugs Discovery, by Country USD Million (2022-2027)
  • Table 114. South America DNA Sequencing In Drugs Discovery, by Type USD Million (2022-2027)
  • Table 115. South America DNA Sequencing In Drugs Discovery, by Method USD Million (2022-2027)
  • Table 116. South America DNA Sequencing In Drugs Discovery, by End User USD Million (2022-2027)
  • Table 117. Brazil DNA Sequencing In Drugs Discovery, by Type USD Million (2022-2027)
  • Table 118. Brazil DNA Sequencing In Drugs Discovery, by Method USD Million (2022-2027)
  • Table 119. Brazil DNA Sequencing In Drugs Discovery, by End User USD Million (2022-2027)
  • Table 120. Argentina DNA Sequencing In Drugs Discovery, by Type USD Million (2022-2027)
  • Table 121. Argentina DNA Sequencing In Drugs Discovery, by Method USD Million (2022-2027)
  • Table 122. Argentina DNA Sequencing In Drugs Discovery, by End User USD Million (2022-2027)
  • Table 123. Rest of South America DNA Sequencing In Drugs Discovery, by Type USD Million (2022-2027)
  • Table 124. Rest of South America DNA Sequencing In Drugs Discovery, by Method USD Million (2022-2027)
  • Table 125. Rest of South America DNA Sequencing In Drugs Discovery, by End User USD Million (2022-2027)
  • Table 126. Asia Pacific DNA Sequencing In Drugs Discovery, by Country USD Million (2022-2027)
  • Table 127. Asia Pacific DNA Sequencing In Drugs Discovery, by Type USD Million (2022-2027)
  • Table 128. Asia Pacific DNA Sequencing In Drugs Discovery, by Method USD Million (2022-2027)
  • Table 129. Asia Pacific DNA Sequencing In Drugs Discovery, by End User USD Million (2022-2027)
  • Table 130. China DNA Sequencing In Drugs Discovery, by Type USD Million (2022-2027)
  • Table 131. China DNA Sequencing In Drugs Discovery, by Method USD Million (2022-2027)
  • Table 132. China DNA Sequencing In Drugs Discovery, by End User USD Million (2022-2027)
  • Table 133. Japan DNA Sequencing In Drugs Discovery, by Type USD Million (2022-2027)
  • Table 134. Japan DNA Sequencing In Drugs Discovery, by Method USD Million (2022-2027)
  • Table 135. Japan DNA Sequencing In Drugs Discovery, by End User USD Million (2022-2027)
  • Table 136. India DNA Sequencing In Drugs Discovery, by Type USD Million (2022-2027)
  • Table 137. India DNA Sequencing In Drugs Discovery, by Method USD Million (2022-2027)
  • Table 138. India DNA Sequencing In Drugs Discovery, by End User USD Million (2022-2027)
  • Table 139. South Korea DNA Sequencing In Drugs Discovery, by Type USD Million (2022-2027)
  • Table 140. South Korea DNA Sequencing In Drugs Discovery, by Method USD Million (2022-2027)
  • Table 141. South Korea DNA Sequencing In Drugs Discovery, by End User USD Million (2022-2027)
  • Table 142. Australia DNA Sequencing In Drugs Discovery, by Type USD Million (2022-2027)
  • Table 143. Australia DNA Sequencing In Drugs Discovery, by Method USD Million (2022-2027)
  • Table 144. Australia DNA Sequencing In Drugs Discovery, by End User USD Million (2022-2027)
  • Table 145. Rest of Asia-Pacific DNA Sequencing In Drugs Discovery, by Type USD Million (2022-2027)
  • Table 146. Rest of Asia-Pacific DNA Sequencing In Drugs Discovery, by Method USD Million (2022-2027)
  • Table 147. Rest of Asia-Pacific DNA Sequencing In Drugs Discovery, by End User USD Million (2022-2027)
  • Table 148. Europe DNA Sequencing In Drugs Discovery, by Country USD Million (2022-2027)
  • Table 149. Europe DNA Sequencing In Drugs Discovery, by Type USD Million (2022-2027)
  • Table 150. Europe DNA Sequencing In Drugs Discovery, by Method USD Million (2022-2027)
  • Table 151. Europe DNA Sequencing In Drugs Discovery, by End User USD Million (2022-2027)
  • Table 152. Germany DNA Sequencing In Drugs Discovery, by Type USD Million (2022-2027)
  • Table 153. Germany DNA Sequencing In Drugs Discovery, by Method USD Million (2022-2027)
  • Table 154. Germany DNA Sequencing In Drugs Discovery, by End User USD Million (2022-2027)
  • Table 155. France DNA Sequencing In Drugs Discovery, by Type USD Million (2022-2027)
  • Table 156. France DNA Sequencing In Drugs Discovery, by Method USD Million (2022-2027)
  • Table 157. France DNA Sequencing In Drugs Discovery, by End User USD Million (2022-2027)
  • Table 158. Italy DNA Sequencing In Drugs Discovery, by Type USD Million (2022-2027)
  • Table 159. Italy DNA Sequencing In Drugs Discovery, by Method USD Million (2022-2027)
  • Table 160. Italy DNA Sequencing In Drugs Discovery, by End User USD Million (2022-2027)
  • Table 161. United Kingdom DNA Sequencing In Drugs Discovery, by Type USD Million (2022-2027)
  • Table 162. United Kingdom DNA Sequencing In Drugs Discovery, by Method USD Million (2022-2027)
  • Table 163. United Kingdom DNA Sequencing In Drugs Discovery, by End User USD Million (2022-2027)
  • Table 164. Netherlands DNA Sequencing In Drugs Discovery, by Type USD Million (2022-2027)
  • Table 165. Netherlands DNA Sequencing In Drugs Discovery, by Method USD Million (2022-2027)
  • Table 166. Netherlands DNA Sequencing In Drugs Discovery, by End User USD Million (2022-2027)
  • Table 167. Rest of Europe DNA Sequencing In Drugs Discovery, by Type USD Million (2022-2027)
  • Table 168. Rest of Europe DNA Sequencing In Drugs Discovery, by Method USD Million (2022-2027)
  • Table 169. Rest of Europe DNA Sequencing In Drugs Discovery, by End User USD Million (2022-2027)
  • Table 170. MEA DNA Sequencing In Drugs Discovery, by Country USD Million (2022-2027)
  • Table 171. MEA DNA Sequencing In Drugs Discovery, by Type USD Million (2022-2027)
  • Table 172. MEA DNA Sequencing In Drugs Discovery, by Method USD Million (2022-2027)
  • Table 173. MEA DNA Sequencing In Drugs Discovery, by End User USD Million (2022-2027)
  • Table 174. Middle East DNA Sequencing In Drugs Discovery, by Type USD Million (2022-2027)
  • Table 175. Middle East DNA Sequencing In Drugs Discovery, by Method USD Million (2022-2027)
  • Table 176. Middle East DNA Sequencing In Drugs Discovery, by End User USD Million (2022-2027)
  • Table 177. Africa DNA Sequencing In Drugs Discovery, by Type USD Million (2022-2027)
  • Table 178. Africa DNA Sequencing In Drugs Discovery, by Method USD Million (2022-2027)
  • Table 179. Africa DNA Sequencing In Drugs Discovery, by End User USD Million (2022-2027)
  • Table 180. North America DNA Sequencing In Drugs Discovery, by Country USD Million (2022-2027)
  • Table 181. North America DNA Sequencing In Drugs Discovery, by Type USD Million (2022-2027)
  • Table 182. North America DNA Sequencing In Drugs Discovery, by Method USD Million (2022-2027)
  • Table 183. North America DNA Sequencing In Drugs Discovery, by End User USD Million (2022-2027)
  • Table 184. United States DNA Sequencing In Drugs Discovery, by Type USD Million (2022-2027)
  • Table 185. United States DNA Sequencing In Drugs Discovery, by Method USD Million (2022-2027)
  • Table 186. United States DNA Sequencing In Drugs Discovery, by End User USD Million (2022-2027)
  • Table 187. Canada DNA Sequencing In Drugs Discovery, by Type USD Million (2022-2027)
  • Table 188. Canada DNA Sequencing In Drugs Discovery, by Method USD Million (2022-2027)
  • Table 189. Canada DNA Sequencing In Drugs Discovery, by End User USD Million (2022-2027)
  • Table 190. Mexico DNA Sequencing In Drugs Discovery, by Type USD Million (2022-2027)
  • Table 191. Mexico DNA Sequencing In Drugs Discovery, by Method USD Million (2022-2027)
  • Table 192. Mexico DNA Sequencing In Drugs Discovery, by End User USD Million (2022-2027)
  • Table 193. DNA Sequencing In Drugs Discovery: by Type(USD/Units)
  • Table 194. Research Programs/Design for This Report
  • Table 195. Key Data Information from Secondary Sources
  • Table 196. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global DNA Sequencing In Drugs Discovery: by Type USD Million (2016-2021)
  • Figure 5. Global DNA Sequencing In Drugs Discovery: by Method USD Million (2016-2021)
  • Figure 6. Global DNA Sequencing In Drugs Discovery: by End User USD Million (2016-2021)
  • Figure 7. South America DNA Sequencing In Drugs Discovery Share (%), by Country
  • Figure 8. Asia Pacific DNA Sequencing In Drugs Discovery Share (%), by Country
  • Figure 9. Europe DNA Sequencing In Drugs Discovery Share (%), by Country
  • Figure 10. MEA DNA Sequencing In Drugs Discovery Share (%), by Country
  • Figure 11. North America DNA Sequencing In Drugs Discovery Share (%), by Country
  • Figure 12. Global DNA Sequencing In Drugs Discovery: by Type USD/Units (2016-2021)
  • Figure 13. Global DNA Sequencing In Drugs Discovery share by Players 2021 (%)
  • Figure 14. Global DNA Sequencing In Drugs Discovery share by Players (Top 3) 2021(%)
  • Figure 15. BCG Matrix for key Companies
  • Figure 16. Illumina (United States) Revenue, Net Income and Gross profit
  • Figure 17. Illumina (United States) Revenue: by Geography 2021
  • Figure 18. Bio Basic (Canada) Revenue, Net Income and Gross profit
  • Figure 19. Bio Basic (Canada) Revenue: by Geography 2021
  • Figure 20. Pacific Biosciences (United States) Revenue, Net Income and Gross profit
  • Figure 21. Pacific Biosciences (United States) Revenue: by Geography 2021
  • Figure 22. QIAGEN (Germany) Revenue, Net Income and Gross profit
  • Figure 23. QIAGEN (Germany) Revenue: by Geography 2021
  • Figure 24. F. Hoffmann-La Roche Ltd. (Switzerland) Revenue, Net Income and Gross profit
  • Figure 25. F. Hoffmann-La Roche Ltd. (Switzerland) Revenue: by Geography 2021
  • Figure 26. Thermo Fischer Scientific Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 27. Thermo Fischer Scientific Inc. (United States) Revenue: by Geography 2021
  • Figure 28. Promega Corporation (United States) Revenue, Net Income and Gross profit
  • Figure 29. Promega Corporation (United States) Revenue: by Geography 2021
  • Figure 30. Global DNA Sequencing In Drugs Discovery: by Type USD Million (2022-2027)
  • Figure 31. Global DNA Sequencing In Drugs Discovery: by Method USD Million (2022-2027)
  • Figure 32. Global DNA Sequencing In Drugs Discovery: by End User USD Million (2022-2027)
  • Figure 33. South America DNA Sequencing In Drugs Discovery Share (%), by Country
  • Figure 34. Asia Pacific DNA Sequencing In Drugs Discovery Share (%), by Country
  • Figure 35. Europe DNA Sequencing In Drugs Discovery Share (%), by Country
  • Figure 36. MEA DNA Sequencing In Drugs Discovery Share (%), by Country
  • Figure 37. North America DNA Sequencing In Drugs Discovery Share (%), by Country
  • Figure 38. Global DNA Sequencing In Drugs Discovery: by Type USD/Units (2022-2027)
List of companies from research coverage that are profiled in the study
  • Illumina (United States)
  • Bio Basic (Canada)
  • Pacific Biosciences (United States)
  • QIAGEN (Germany)
  • F. Hoffmann-La Roche Ltd. (Switzerland)
  • Thermo Fischer Scientific Inc. (United States)
  • Promega Corporation (United States)
Select User Access Type

Key Highlights of Report


Jul 2022 206 Pages 97 Tables Base Year: 2021 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The standard version of the report profiles players such as Illumina (United States), Bio Basic (Canada), Pacific Biosciences (United States), QIAGEN (Germany), F. Hoffmann-La Roche Ltd. (Switzerland), Thermo Fischer Scientific Inc. (United States) and Promega Corporation (United States) etc.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
"Technological Innovation and Advancement in DNA Sequencing in Drug Discovery" is seen as one of major influencing trends for DNA Sequencing In Drugs Discovery Market during projected period 2021-2027.
The DNA Sequencing In Drugs Discovery market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete company list in our research coverage.

Know More About Global DNA Sequencing In Drugs Discovery Market Report?